Tan S, Ignatenko S, Wagner F, et al. - Since the dual sodium-glucose co-transporter 1/2 inhibitor (SGLT1/2i) licogliflozin (LIK066) alleviates hyperinsulinism in patients with diabetes and obesity, researchers conducted this multicentre, randomized, placebo-controlled, double-blind, 2-week trial to investigate the impact of licogliflozin on androgens in women with PCOS. For this trial, patients with PCOS were given either licogliflozin 50 mg or placebo three times a day (TID). Changes in free testosterone, other androgens, and insulin resistance variables were studied. Common adverse events included diarrhoea and nausea. In women with PCOS, dual inhibition of SGLT1/2 improves hyperinsulinaemia and hyperandrogenaemia. Licogliflozin could be a promising new treatment option for PCOS.